Fulgent Genetics Inc

FLGT

Equity

ISIN null / Valor 33851033

NASDAQ (2026-10-01)

USD 21.30-3.27%

Fulgent Genetics Inc
UMushroom community rating:

4.50 2 votes No rating yet

NegativeNeutralPositive

About company

Fulgent Genetics Inc, founded in 2011, is a leading genomic testing company in the United States, offering a wide range of genetic testing services including single gene tests, rare disease tests, whole genome sequencing, copy number variation analysis, mitochondrial sequencing, and quality sequencing services. With 7 CLIA-certified and CAP-accredited labs across the country, Fulgent maintains high standards in diagnostic testing. In addition to its testing services, the company is also involved in therapeutic development, focusing on developing drug candidates for various cancers using innovative nanoencapsulation and targeted therapy approaches. By combining its expertise in testing and drug development, Fulgent aims to become a fully integrated precision medicine company, with a focus on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-9.36%1Y

-20.3%3Y

-74.7%5Y

Performance

66.2%1Y

51.3%3Y

51.9%5Y

Volatility

586 M

Market cap (USD)

338,225

Daily traded volume (Shares)

18.64 / 17.8

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.50

2 votes

Performance:

4.50

Innovation:

5.00

Society:

4.00

Nature:

4.00

Maryam Jaouad

UK, 08 Nov 2025

Fulgent Genetics remains a strong player in genomic testing and precision medicine, leveraging AI and NGS platforms to expand its diagnostics portfolio. While growth has slowed post-COVID, innovation in oncology and genetic screening supports long-term value.